Posted on February 24th, 2015
by James Joyce
During a presentation last November, I provided guidance on near-term Hemopurifier® clinical progression goals. Among the stated goals, which we subsequently achieved, were the reporting of Ebola virus treatment data, the disclosure of our Medanta Medicity Hepatitis C study final results and the initiation of our first FDA approved clinical study.
However, I also provided guidance related to our Exosome Sciences diagnostic subsidiary that was off target. Based on an invitation to present at an event that was to be held prior to the NFL Super Bowl, I indicated the goal of reporting our first Chronic Traumatic Encephalopathy (CTE) research data prior to the end of January. Unfortunately, this event was postponed. As previously disclosed, our CTE research is being conducted through a clinical collaboration with the Boston University (BU) CTE Center. Our goal is to advance a blood-based diagnostic candidate that could identify CTE in living individuals. At present, this neurodegenerative disorder can only be diagnosed through postmortem autopsy.
Our CTE data is now scheduled to be presented at 11:00 am on April 16th at the 2015 TBI Conference in Washington, DC. The presentation is entitled: “Detecting Tau: State of the Art Potential Biomarkers for Chronic Traumatic Encephalopathy”
The presenter will be Robert A. Stern, Ph.D., Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology, Director of Clinical Research, CTE Center, Clinical Core Director, BU Alzheimer’s Disease Center, Boston University School of Medicine
The description of the presentation on the TBI Conference website follows:
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with a history of repetitive brain trauma. At this time, the diagnosis of CTE can only be made through neuropathological examination. However, in order to investigate critical issues pertaining to CTE, such as its incidence and prevalence and specific risk factors, as well as to conduct clinical trials for the prevention and treatment of the disease, it is necessary to develop accurate methods of in vivo diagnosis. A hallmark feature of the neuropathology of CTE is the deposition of hyperphosphorylated tau (p-tau) as neurofibrillary tangles (NFT) beginning perivascularly and at the depths of the cortical sulci. This talk will present data from the DETECT study of former professional American football players, focusing on preliminary findings of two potential biomarkers for p-tau in CTE: (1) a blood-based measure of brain-derived exosomal tau (Exosome Sciences) and the T807 (AV1451) PET tau radiotracer (Avid Radiopharmaceutical).
To learn more about the conference, visit www.tbiconference.com
Forward Looking Statements
This blog contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary. will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.